<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39647">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590263</url>
  </required_header>
  <id_info>
    <org_study_id>M13-714</org_study_id>
    <nct_id>NCT02590263</nct_id>
  </id_info>
  <brief_title>Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma</brief_title>
  <official_title>A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety
      of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health
      Organization (WHO) grade III or IV malignant glioma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events</measure>
    <time_frame>At each visit for approximately 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ABT-414</measure>
    <time_frame>Multiple time points in Cycles 1, 2 and 3 (4 weeks each) and Day 1 of remaining cycles until end of treatment for approximately 1 year for recurrent subjects and in every week of Day 1 until Week 7 and end of treatment for the newly diagnosed subjects</time_frame>
    <description>Assessed during the Phase 1 portion of the study, the maximum plasma concentration (Cmax) is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities</measure>
    <time_frame>At each visit for approximately 1 year</time_frame>
    <description>Measurement by clinical lab results, vital signs, physical exam and electrocardiogram (ECG) during the Phase 1 portion of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of ABT-414</measure>
    <time_frame>Multiple time points in Cycles 1, 2 and 3 (4 weeks each) and Day 1 of remaining cycles until end of treatment for approximately 1 year for recurrent subjects and in every week of Day 1 until Week 7 and end of treatment for the newly diagnosed subjects</time_frame>
    <description>Assessed during the Phase 1 portion of the study, the area under the plasma concentration-time curve (AUC) is a method of measurement to determine the total exposure of a drug in blood plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At each visit for approximately 1 year</time_frame>
    <description>Time to progression-free survival is defined as the number of days from the date of first dose to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria or to the date of death, if disease progression does not occur (except Arm B of Phase 1 portion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At each visit for approximately 1 year</time_frame>
    <description>Overall survival is defined as number of days from the date of first dose to the date of death for all dosed participants (except Arm B of Phase 1 portion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At each visit for approximately 1 year</time_frame>
    <description>The objective response rate is defined as the proportion of participants with at least one measurable lesion at baseline who achieves a confirmed complete (CR) or partial response (PR) based on RANO criteria (except Arm B of Phase 1 portion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response</measure>
    <time_frame>At each visit for approximately 1 year</time_frame>
    <description>The duration of overall response for a given participant is defined as the number of days from the day the RANO criteria are met for CR or PR (whichever is recorded first) to the date that progressive disease (PD) is objectively documented (based RANO criteria) (except Arm B of Phase 1 portion).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Malignant Glioma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm A of Phase 1 portion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-414 administered every other weeks monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B of Phase 1 portion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-414 administered every other weeks in combination with radiation and temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 portion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-414 administered every other weeks in combination with temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-414</intervention_name>
    <description>ABT-414 will be administered by intravenous infusion</description>
    <arm_group_label>Arm A of Phase 1 portion</arm_group_label>
    <arm_group_label>Arm B of Phase 1 portion</arm_group_label>
    <arm_group_label>Phase 2 portion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide will be administered per label.</description>
    <arm_group_label>Arm B of Phase 1 portion</arm_group_label>
    <arm_group_label>Phase 2 portion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Brain Radiation</intervention_name>
    <description>Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.</description>
    <arm_group_label>Arm B of Phase 1 portion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese participants with WHO grade III or IV malignant glioma in Phase 1 portion or
             WHO grade IV GBM in Phase 2 portion

          -  70 or above on Karnofsky Performance Status in Arm A of Phase 1 portion and Phase 2
             portion

          -  80 or above on Karnofsky Performance Status in Arm B of Phase 1 portion

          -  Adequate bone marrow function

          -  Recurrent malignant glioma per RANO criteria in Arm A of Phase 1 portion and Phase 2
             portion

          -  Histologically proven newly diagnosed malignant glioma in Arm B of Phase 1 portion

          -  Participants must have confirmed EGFR amplification by central lab in Phase 2 portion

        Exclusion Criteria:

          -  Anti-cancer treatment 28 days prior to study Day 1 for Arm A of Phase 1 portion and
             Phase 2 portion (except temozolomide therapy for newly diagnosed treatment for Phase
             2 portion)

          -  Anti-cancer treatment prior to study Day 1 for Arm B of Phase 1 portion

          -  Participant has received prior treatment with bevacizumab, for recurrent
             glioblastoma, EGFR therapy or has secondary grade IV GBM in Phase 2 portion

          -  Participant has a history of major immunologic reaction to any Immunoglobulin G
             containing agents or component of ABT-414.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AbbVie_GK Clinical_Trial_Registration_Desk</last_name>
    <email>AbbVie_JPN_info_clingov@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140361</name>
      <address>
        <city>Hidaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140361, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 139399</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 139399, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149385</name>
      <address>
        <city>Itabashi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149385, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138558</name>
      <address>
        <city>Kumamoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138558, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140437</name>
      <address>
        <city>Kyoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140437, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149093</name>
      <address>
        <city>Kyoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149093, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140360</name>
      <address>
        <city>Mitaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140360, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149145</name>
      <address>
        <city>Morioka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149145, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148673</name>
      <address>
        <city>Nagaizumi-cho</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148673, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138559</name>
      <address>
        <city>Nagoya-shi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138559, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148674</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148674, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148494</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148494, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148493</name>
      <address>
        <city>Sagamihara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148493, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150589</name>
      <address>
        <city>Sapporo-shi, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150589, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138464</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 138464, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150990</name>
      <address>
        <city>Shimotsuka-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150990, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140438</name>
      <address>
        <city>Suita-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140438, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140435</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140435, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140436</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140436, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 140433</name>
      <address>
        <city>Tsukuba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 140433, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>September 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>WHO grade III</keyword>
  <keyword>WHO grade IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
